Atrial fibrillation: Difference between revisions

Jump to navigation Jump to search
m (Robot: Changing Category:Up-To-Date Cardiology to Category:Up-To-Date cardiology)
No edit summary
Line 17: Line 17:
{{CMG}}
{{CMG}}


'''Synonyms and related keywords''': AF, Afib, fib, PAF, paroxysmal afib, Lone fibrillator
'''''Synonyms and related keywords:''''' AF, Afib, fib, PAF, paroxysmal afib, Lone fibrillator


==[[Atrial fibrillation overview|Overview]]==
==[[Atrial fibrillation overview|Overview]]==
Line 25: Line 25:
==[[Atrial fibrillation epidemiology and demographics|Epidemiology and demographics]]==
==[[Atrial fibrillation epidemiology and demographics|Epidemiology and demographics]]==


==[[Atrial fibrillation risk factors | Risk Factors]]==
==[[Atrial fibrillation risk factors|Risk Factors]]==
 
==[[Atrial fibrillation screening|Screening]]==


==[[Atrial fibrillation diagnosis|Diagnosis]]==
==[[Atrial fibrillation diagnosis|Diagnosis]]==
[[Atrial fibrillation symptoms|Symptoms]] | [[Atrial fibrillation screening|Screening]] | [[Atrial fibrillation physical examination|Physical Examination]] | [[Atrial fibrillation laboratory tests|Laboratory Tests]] | [[Atrial fibrillation electrocardiogram|Electrocardiogram]] | [[Atrial fibrillation chest x ray|Chest X ray]] | [[Atrial fibrillation echocardiography or ultrasound|Echocardiography]] | [[Atrial fibrillation other imaging findings#Holter monitoring|Holter monitoring]] | [[Atrial fibrillation other imaging findings#Exercise stress testing|Exercise stress testing]]
[[Atrial fibrillation symptoms|History and Symptoms]] | [[Atrial fibrillation physical examination|Physical Examination]] | [[Atrial fibrillation laboratory tests|Laboratory Tests]] | [[Atrial fibrillation electrocardiogram|Electrocardiogram]] | [[Atrial fibrillation chest x ray|Chest X ray]] | [[Atrial fibrillation echocardiography or ultrasound|Echocardiography]] | [[Atrial fibrillation other imaging findings#Holter monitoring|Holter monitoring]] | [[Atrial fibrillation other imaging findings#Exercise stress testing|Exercise stress testing]]


==Treatment==
==[[Atrial fibrillation overview of treatment|Treatment]]==
===[[Atrial fibrillation urgent treatment|Urgent treatment]]===
===[[Atrial fibrillation urgent treatment|Urgent DC Cardioversion]]===


===[[Atrial fibrillation overview of treatment|Overview and General Treatment Strategies]]===
===Anticoagulation:===
[[Atrial fibrillation anticoagulation|Anticoagulation Overview]] | [[Warfarin]] | [[Dabigatran]] | [[Dabigatran#Converting from or to Warfarin|Converting from or to Warfarin]] | [[Dabigatran#Converting from or to Parenteral Anticoagulants|Converting from or to Parenteral Anticoagulants]]


===Anticoagulation===
=====Dabigatran=====  
[[Atrial fibrillation anticoagulation]] | [[Warfarin]] | [[Dabigatran]]
[[dabigatran#Dosing|Dosing]] | [[Dabigatran#Surgery and Interventions|Discontinuation for Surgery and Interventions]] | [[Dabigatran#WARNINGS AND PRECAUTIONS| Warnings and Precautions]] | [[Dabigatran#Adverse Reactions|Adverse Reactions]] | [[Dabigatran#Use in Specific Populations|Use in Specific Populations Such as Pregnancy]] | [[Dabigatran#Overdosage|Overdosage]] | [[Clinical Pharmacology of Dabigatran|Clinical Pharmacology]] | [[FDA Review of Data From the RE-LY Trial on September 20th, 2010|FDA Review of the RE-LY Data]] | [[A comparison of the RE-LY and Rocket AF Trials ]] | [[Estimates of Cost Per Year of Life Saved for Dabigatran]]


[[Dabigatran#Converting from or to Warfarin|Converting from or to Warfarin]] | [[Dabigatran#Converting from or to Parenteral Anticoagulants|Converting from or to Parenteral Anticoagulants]]  
===[[Atrial fibrillation rate control|Rate control]]===


'''[[Dabigatran]]:''' [[dabigatran#Dosing|Dosing]] | [[Dabigatran#Surgery and Interventions|Discontinuation for Surgery and Interventions]] | [[Dabigatran#WARNINGS AND PRECAUTIONS| Warnings and Precautions]] | [[Dabigatran#Adverse Reactions|Adverse Reactions]] | [[Dabigatran#Use in Specific Populations|Use in Specific Populations Such as Pregnancy]] | [[Dabigatran#Overdosage|Overdosage]] | [[Clinical Pharmacology of Dabigatran|Clinical Pharmacology]] | [[FDA Review of Data From the RE-LY Trial on September 20th, 2010|FDA Review of the RE-LY Data]] | [[A comparison of the RE-LY and Rocket AF Trials ]] | [[Estimates of Cost Per Year of Life Saved for Dabigatran]]
===[[Atrial fibrillation maintenance of sinus rhythm|Maintenance of Sinus Rhythm]]===


===Rate Control===
===Surgical options:===
[[Atrial fibrillation maintenance of sinus rhythm| Maintenance of Sinus Rhythm]] | [[Atrial fibrillation rate control| Rate Control]] | [[Atrial fibrillation cardioversion|Cardioversion]] | [[Atrial fibrillation invasive treatment|Invasive Treatment]] | [[Atrial fibrillation surgical treatment|Surgical Treatment]]
[[Atrial fibrillation cardioversion|Cardioversion]] | [[Atrial fibrillation invasive treatment#Radiofrequency ablation|Radiofrequency ablation]] | [[Atrial fibrillation percutaneous coronary intervention|PCI in Afib]] | [[Atrial fibrillation surgical treatment|Maze Open Heart Surgery]]


===Special Considerations===
==Special Considerations==
[[Postoperative atrial fibrillation|Postoperative AF]] | [[Atrial fibrillation acute myocardial infarction|Acute Myocardial Infarction]] | [[Atrial fibrillation Wolff-Parkinson-White preexcitation syndromes|Wolff-Parkinson-White Preexcitation Syndromes]] | [[Atrial fibrillation hyperthyroidism|Hyperthyroidism]] | [[Atrial fibrillation pregnancy|Pregnancy]] | [[Atrial fibrillation hypertrophic cardiomyopathy|Hypertrophic Cardiomyopathy]] | [[Atrial fibrillation pulmonary diseases|Pulmonary Diseases]]
[[Postoperative atrial fibrillation|Postoperative AF]] | [[Atrial fibrillation acute myocardial infarction|Acute Myocardial Infarction]] | [[Atrial fibrillation Wolff-Parkinson-White preexcitation syndromes|Wolff-Parkinson-White Preexcitation Syndromes]] | [[Atrial fibrillation hypertrophic cardiomyopathy|Hypertrophic Cardiomyopathy]] | [[Atrial fibrillation hyperthyroidism|Hyperthyroidism]] | [[Atrial fibrillation pulmonary diseases|Pulmonary Diseases]] | [[Atrial fibrillation pregnancy|Pregnancy]]  


==[[Atrial fibrillation follow-up and secondary prevention|Follow-Up and Secondary Prevention]]==
==[[Atrial fibrillation secondary prevention|Secondary Prevention]]==


==[[Atrial fibrillation clinical trial data|Clinical Trial Data]]==
==[[Atrial fibrillation clinical trial data|Supportive Trial Data]]==


==Vote on and Suggest Revisions to the Current Guidelines==
==Vote on and Suggest Revisions to the Current Guidelines==

Revision as of 15:00, 3 April 2012

Atrial fibrillation
ICD-10 I48
ICD-9 427.31
DiseasesDB 1065
MedlinePlus 000184

Atrial Fibrillation Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Atrial Fibrillation from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Special Groups

Postoperative AF
Acute Myocardial Infarction
Wolff-Parkinson-White Preexcitation Syndrome
Hypertrophic Cardiomyopathy
Hyperthyroidism
Pulmonary Diseases
Pregnancy
ACS and/or PCI or valve intervention
Heart failure

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

EKG Examples
A-Fib with LBBB

Chest X Ray

Echocardiography

Holter Monitoring and Exercise Stress Testing

Cardiac MRI

Treatment

Rate and Rhythm Control

Cardioversion

Overview
Electrical Cardioversion
Pharmacological Cardioversion

Anticoagulation

Overview
Warfarin
Converting from or to Warfarin
Converting from or to Parenteral Anticoagulants
Dabigatran

Maintenance of Sinus Rhythm

Surgery

Catheter Ablation
AV Nodal Ablation
Surgical Ablation
Cardiac Surgery

Specific Patient Groups

Primary Prevention

Secondary Prevention

Supportive Trial Data

Cost-Effectiveness of Therapy

Case Studies

Case #1

Atrial fibrillation On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Atrial fibrillation

CDC on Atrial fibrillation

Atrial fibrillation in the news

Blogs on Atrial fibrillation

Directions to Hospitals Treating Atrial fibrillation

Risk calculators and risk factors for Atrial fibrillation

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and related keywords: AF, Afib, fib, PAF, paroxysmal afib, Lone fibrillator

Overview

Pathophysiology

Epidemiology and demographics

Risk Factors

Screening

Diagnosis

History and Symptoms | Physical Examination | Laboratory Tests | Electrocardiogram | Chest X ray | Echocardiography | Holter monitoring | Exercise stress testing

Treatment

Urgent DC Cardioversion

Anticoagulation:

Anticoagulation Overview | Warfarin | Dabigatran | Converting from or to Warfarin | Converting from or to Parenteral Anticoagulants

Dabigatran

Dosing | Discontinuation for Surgery and Interventions | Warnings and Precautions | Adverse Reactions | Use in Specific Populations Such as Pregnancy | Overdosage | Clinical Pharmacology | FDA Review of the RE-LY Data | A comparison of the RE-LY and Rocket AF Trials | Estimates of Cost Per Year of Life Saved for Dabigatran

Rate control

Maintenance of Sinus Rhythm

Surgical options:

Cardioversion | Radiofrequency ablation | PCI in Afib | Maze Open Heart Surgery

Special Considerations

Postoperative AF | Acute Myocardial Infarction | Wolff-Parkinson-White Preexcitation Syndromes | Hypertrophic Cardiomyopathy | Hyperthyroidism | Pulmonary Diseases | Pregnancy

Secondary Prevention

Supportive Trial Data

Vote on and Suggest Revisions to the Current Guidelines

Guideline Resources

Related Chapters

External links

References

  1. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. (2006) ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114 (7):e257-354. DOI:10.1161/CIRCULATIONAHA.106.177292 PMID: 16908781
  2. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. (2011) 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 123 (10):e269-367. DOI:10.1161/CIR.0b013e318214876d PMID: 21382897
  3. Estes NA, Halperin JL, Calkins H, Ezekowitz MD, Gitman P, Go AS et al. (2008) ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation): developed in collaboration with the Heart Rhythm Society. Circulation 117 (8):1101-20. DOI:10.1161/CIRCULATIONAHA.107.187192 PMID: 18283199

de:Vorhofflimmern it:Fibrillazione atriale nl:Boezemfibrilleren no:Atrieflimmer fi:Eteisvärinä


Template:WikiDoc Sources